Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Cash & Equivalents (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Cash & Equivalents data on record, last reported at $142.2 million in Q3 2020.

  • For Q3 2020, Cash & Equivalents changed N/A year-over-year to $142.2 million; the TTM value through Sep 2020 reached $142.2 million, changed N/A, while the annual FY2019 figure was $61.1 million, N/A changed from the prior year.
  • Cash & Equivalents reached $142.2 million in Q3 2020 per KLRS's latest filing, up from $78.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $168.6 million in Q1 2020 and bottomed at $61.1 million in Q4 2019.